Tysabri To Be Priced 20% Higher Than When Initially Launched
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.
You may also be interested in...
Elan Outlines Options For Tysabri If Biogen Idec Is Sold
Larger pharmas, including Pfizer and Johnson & Johnson, are likely among the potential acquirers.
Elan Outlines Options For Tysabri If Biogen Idec Is Sold
Larger pharmas, including Pfizer and Johnson & Johnson, are likely among the potential acquirers.
Elan Eyes Tysabri sBLA For Crohn’s In U.S.
Biologic could be positioned as a monotherapy.